RÉSUMÉ
BACKGROUND: The 'Questions and Answers (Q&A)' document regarding Japanese biosimilar guideline elucidated that Japanese participant enrollment in at least one comparative clinical study was required for the marketing authorization application (MAA) of biosimilars in Japan. RESEARCH DESIGN AND METHODS: To discuss the requirement of Japanese clinical study data for biosimilar development, the trend in comparative clinical studies conducted for approved biosimilars of monoclonal antibodies and fusion proteins was analyzed, and the consistency of the results between the overall population and the Japanese population according to the publicly available information was reviewed. RESULTS: The number of comparative clinical studies enrolling Japanese participants was 25 cases, and the type and percentage were 13 (52%) and 12 (48%) cases of comparative pharmacokinetic study and comparative efficacy study, respectively. In all comparative clinical studies, consistent results between the overall population and the Japanese population were shown. CONCLUSIONS: Our study indicated that Japanese participant enrollment in comparative clinical studies may not always be necessary for biosimilar development when certain conditions are satisfied. This has been described in the revised Q&A document published by the Ministry of Health, Labour and Welfare in January 2024.
Sujet(s)
Produits pharmaceutiques biosimilaires , Produits pharmaceutiques biosimilaires/usage thérapeutique , Produits pharmaceutiques biosimilaires/pharmacocinétique , Japon , Humains , Agrément de médicaments , Essais cliniques comme sujet , Développement de médicament/tendances , Peuples d'Asie de l'EstRÉSUMÉ
HIV vaccine development has been hindered by significant challenges over four decades. Despite persistent efforts, all efficacy trials to date have yielded disappointing results. This has pushed the field back to the discovery phase and created uncertainty about the future involvement of large pharmaceutical companies. Currently, the HIV vaccine landscape is dominated by startup biotech firms, which face a complex array of obstacles. These include evolving HIV prevention methods, waning interest in vaccine research, and difficulties securing sustainable funding. This viewpoint explores the challenges faced by these biotech companies and the support mechanisms necessary for their continued involvement in HIV vaccine development. By leveraging insights from both pharmaceutical and biotech sectors, we propose a multi-faceted approach that includes enhanced communication, fostering innovation, and implementing strategic funding models.
Sujet(s)
Vaccins contre le SIDA , Biotechnologie , Infections à VIH , Développement de vaccin , Vaccins contre le SIDA/immunologie , Vaccins contre le SIDA/administration et posologie , Humains , Infections à VIH/prévention et contrôle , Industrie pharmaceutique/économie , Développement de médicament/tendances , Développement de médicament/économieRÉSUMÉ
Antibody-drug conjugates (ADCs), from prototypes in the 1980s to first- and second-generation products in the 2000s, and now in their multiformats, have progressed tremendously to meet oncological challenges. Currently, 13 ADCs have been approved for medical practice, with over 200 candidates in clinical trials. Moreover, ADCs have evolved into different formats, including bispecific ADCs, probody-drug conjugates, pH-responsive ADCs, target-degrading ADCs, and immunostimulating ADCs. Technologies from biopharmaceutical industries have a crucial role in the clinical transition of these novel biotherapeutics. In this review, we highlight several features contributing to the prosperity of bioindustrial ADC development. Various proprietary technologies from biopharmaceutical companies are discussed. Such advances in biopharmaceutical industries are the backbone for the success of ADCs in development and clinical application.
Sujet(s)
Biotechnologie , Développement de médicament , Industrie pharmaceutique , Immunoconjugués , Immunoconjugués/usage thérapeutique , Immunoconjugués/administration et posologie , Humains , Biotechnologie/méthodes , Industrie pharmaceutique/méthodes , Développement de médicament/méthodes , Développement de médicament/tendances , AnimauxSujet(s)
Développement de médicament , Maladies parasitaires , Humains , Animaux , Maladies parasitaires/prévention et contrôle , Maladies parasitaires/traitement médicamenteux , Développement de médicament/tendances , Conception de médicament , Parasitoses animales/traitement médicamenteux , Parasitoses animales/prévention et contrôle , Antiparasitaires/usage thérapeutiqueRÉSUMÉ
Artificial intelligence and machine learning enable the construction of predictive models, which are currently used to assist in decision-making throughout the process of drug discovery and development. These computational models can be used to represent the heterogeneity of a disease, identify therapeutic targets, design and optimize drug candidates, and evaluate the efficacy of these drugs on virtual patients or digital twins. By combining detailed patient characteristics with the prediction of potential drug-candidate properties, artificial intelligence promotes the emergence of a "computational" precision medicine, allowing for more personalized treatments, better tailored to patient specificities with the aid of such predictive models. Based on such new capabilities, a mixed reality approach to the development of new drugs is being adopted by the pharmaceutical industry, which integrates the outputs of predictive virtual models with real-world empirical studies.
Title: L'intelligence artificielle, une révolution dans le développement des médicaments. Abstract: L'intelligence artificielle (IA) et l'apprentissage automatique produisent des modèles prédictifs qui aident à la prise de décisions dans le processus de découverte de nouveaux médicaments. Cette modélisation par ordinateur permet de représenter l'hétérogénéité d'une maladie, d'identifier des cibles thérapeutiques, de concevoir et optimiser des candidats-médicaments et d'évaluer ces médicaments sur des patients virtuels, ou des jumeaux numériques. En facilitant à la fois une connaissance détaillée des caractéristiques des patients et en prédisant les propriétés de multiples médicaments possibles, l'IA permet l'émergence d'une médecine de précision « computationnelle ¼ offrant des traitements parfaitement adaptés aux spécificités des patients.
Sujet(s)
Intelligence artificielle , Développement de médicament , Médecine de précision , Intelligence artificielle/tendances , Humains , Développement de médicament/méthodes , Développement de médicament/tendances , Médecine de précision/méthodes , Médecine de précision/tendances , Découverte de médicament/méthodes , Découverte de médicament/tendances , Apprentissage machine , Simulation numériqueRÉSUMÉ
The challenge of antimicrobial resistance is broadly appreciated by the clinical and scientific communities. To assess progress in the development of medical countermeasures to combat bacterial infections, we deployed information gleaned from clinical trials conducted from 2000 to 2021. Whereas private sector interest in cancer grew dramatically over this period, activity to combat bacterial infections remained stagnant. The comparative ambivalence to antimicrobial resistance is reflected in the number of investigative drugs under clinical investigation, their stage of development and most troublingly, a declining number of organizations that are actively involved in the development of new products to treat bacterial infections. This drop reflects the exits of many companies that had previously developed antibacterial agents.
Sujet(s)
Antibactériens , Infections bactériennes , Développement de médicament , Humains , Antibactériens/pharmacologie , Antibactériens/usage thérapeutique , Infections bactériennes/traitement médicamenteux , Infections bactériennes/microbiologie , Développement de médicament/méthodes , Développement de médicament/tendances , Résistance bactérienne aux médicaments , Animaux , Essais cliniques comme sujet , Découverte de médicament/méthodes , Découverte de médicament/tendancesSujet(s)
Essais cliniques comme sujet , Diabète de type 1 , Développement de médicament , Hypoglycémiants , Humains , Diabète de type 1/traitement médicamenteux , Développement de médicament/tendances , Développement de médicament/méthodes , Détermination du point final , Hypoglycémiants/usage thérapeutiqueSujet(s)
Africains , Intelligence artificielle , Développement de médicament , Personnel de recherche , Afrique , Intelligence artificielle/tendances , Développement de médicament/méthodes , Développement de médicament/tendances , Recherche biomédicale/méthodes , Recherche biomédicale/tendances , Bases de données comme sujet , Personnel de recherche/tendancesRÉSUMÉ
Bajo el lema Transformando la sanidad con el farmacéutico, el 23 Congreso Nacional Farmacéutico ha reunido en Valencia a más de 2.000 farmacéuticos de todos los ámbitos de la profesión, desde la óptica y la ortopedia, a la dermofarmacia, la investigación, la industria, la distribución, la alimentación, los análisis clínicos, la salud pública, la farmacia hospitalaria y, por supuesto, la farmacia comunitaria. (AU)
Sujet(s)
Humains , Pharmaciens/tendances , Biopharmacie/tendances , Recherche pharmaceutique/tendances , Sociétés de pharmaciens/tendances , Développement de médicament/tendancesRÉSUMÉ
Introduction: The COVID-19 pandemic had a profound impact on vaccines' Research and Development, on vaccines' market, and on immunization programmes and policies. The need to promptly respond to the health emergency boostered resources' al-location and innovation, while new technologies were made available. Regulatory procedures were revised and expedited, and global production and distribution capacities significantly increased. Aim of this review is to outline the trajectory of research in vaccinology and vaccines' pipeline, highlighting major challenges and opportunities, and projecting future perspectives in vaccine preventables diseases' prevention and control. Study Design: Narrative review. Methods: We comprehensively consulted key biomedical databases including "Medline" and "Embase", preprint platforms, including"MedRxiv" and "BioRxiv", clinical trial registries, selected grey literature sources and scientific reports. Further data and insights were collected from experts in the field. We first reflect on the impact that the COVID-19 had on vaccines' Research and Development, regulatory frameworks, and market, we then present updated figures of vaccines pipeline, by different technologies, comparatively highlighting advantages and disadvantages. We conclude summarizing future perspectives in vaccines' development and immunizations strategies, outlining key challenges, knowledge gaps and opportunities for prevention strategies. Results: COVID-19 vaccines' development has been largely supported by public funding. New technologies and expetited autho-rization and distribution processes allowed to control the pandemic, leading vaccines' market to grow exponentially. In the post-pandemic era investments in prevention are projected to decrease but advancements in technology offer great potential to future immunization strategies. As of 2023, the vaccine pipeline include almost 1,000 candidates, at different Research and Development phase, including innovative recombinant protein vaccines, nucleic acid vaccines and viral vector vaccines. Vaccines' technology platforms development varies by disease. Overall, vaccinology is progressing towards increasingly safe and effective products that are easily manufacturable and swiftly convertible. Conclusions: Vaccine research is rapidly evolving, emerging technologies and new immunization models offer public health new tools and large potential to fight vaccines preventables diseases, with promising new platforms and broadened target populations. Real-life data analysis and operational research is needed to evaluate how such potential is exploited in public health practice to improve population health.
Sujet(s)
Vaccins contre la COVID-19 , COVID-19 , Développement de vaccin , Humains , COVID-19/prévention et contrôle , COVID-19/épidémiologie , Vaccins contre la COVID-19/administration et posologie , Pandémies/prévention et contrôle , Prévision , Recherche biomédicale/tendances , Vaccinologie/tendances , Vaccinologie/méthodes , Programmes de vaccination/tendances , Développement de médicament/tendancesRÉSUMÉ
Coronavirus disease 2019 (COVID-19) epidemiology and product landscapes have changed considerably since onset of the pandemic. Safe and effective vaccines and therapeutics are available, but the continual emergence of severe acute respiratory syndrome coronavirus 2 variants introduce limitations in our ability to prevent and treat disease. Project NextGen is a collaboration between the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response, and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, that is leveraging public-private partnerships to address gaps in the nation's COVID-19 vaccine and therapeutic capabilities. Targeted investments will advance promising next-generation candidates through the most difficult phases of clinical development to encourage further private sector interest for later stage development and commercial availability. New commercial vaccines and therapeutics that are more durable and effective across variants will improve our fight against COVID-19 and transform our response to future threats.
Sujet(s)
Vaccins contre la COVID-19 , COVID-19 , Partenariats entre secteurs publique et privé , SARS-CoV-2 , Humains , COVID-19/prévention et contrôle , COVID-19/épidémiologie , SARS-CoV-2/immunologie , États-Unis , Développement de vaccin , Traitements médicamenteux de la COVID-19 , Antiviraux/usage thérapeutique , Développement de médicament/tendances , Pandémies/prévention et contrôleRÉSUMÉ
INTRODUCTION: Biosimilar clinical programs could be streamlined by prudent application of improved methodologies and knowledge accumulated over the past 20 years. This review focuses on whether complex comparative efficacy trials are routinely needed and how to achieve a more tailored approach to biosimilar development. AREAS COVERED: Key learnings over the past 20 years are summarized. It is noted that a one size fits all approach to biosimilar development is not appropriate: biological medicines fall within a wide spectrum of complexity, with blurring at the interface between biological products and small molecules. The interrelationship between quality, potency, pharmacokinetics, pharmacology, immunogenicity, efficacy, and safety are reviewed. Current regulatory thinking is reviewed with a look into what future challenges lie ahead. EXPERT OPINION: To tailor regulatory requirements for marketing approval of biosimilars, it is proposed that a biosimilarity report be introduced. This report would integrate quality, pharmacology, immunogenicity, efficacy and safety findings and address how the clinical program could be tailored based on the totality of evidence.
Sujet(s)
Produits pharmaceutiques biosimilaires , Développement de médicament , Produits pharmaceutiques biosimilaires/usage thérapeutique , Produits pharmaceutiques biosimilaires/pharmacocinétique , Humains , Développement de médicament/tendances , Agrément de médicamentsRÉSUMÉ
Antimicrobial resistance (AMR) is a major global health issue. Current measures for tackling it comprise mainly the prudent use of drugs, the development of new drugs, and rapid diagnostics. Relatively little attention has been given to forecasting the evolution of resistance. Here, we argue that forecasting has the potential to be a great asset in our arsenal of measures to tackle AMR. We argue that, if successfully implemented, forecasting resistance will help to resolve the antibiotic crisis in three ways: it will (i) guide a more sustainable use (and therefore lifespan) of antibiotics and incentivize investment in drug development, (ii) reduce the spread of AMR genes and pathogenic microbes in the environment and between patients, and (iii) allow more efficient treatment of persistent infections, reducing the continued evolution of resistance. We identify two important challenges that need to be addressed for the successful establishment of forecasting: (i) the development of bespoke technology that allows stakeholders to empirically assess the risks of resistance evolving during the process of drug development and therapeutic/preventive use, and (ii) the transformative shift in mindset from the current praxis of mostly addressing the problem of antibiotic resistance a posteriori to a concept of a priori estimating, and acting on, the risks of resistance.
Sujet(s)
Antibactériens , Résistance bactérienne aux médicaments , Prévision , Humains , Antibactériens/pharmacologie , Résistance bactérienne aux médicaments/génétique , Évolution moléculaire , Développement de médicament/tendances , Bactéries/effets des médicaments et des substances chimiques , Bactéries/génétiqueRÉSUMÉ
Giardia duodenalis is a protozoan intestinal parasite that causes a significant number of infections worldwide each year, particularly in low-income and developing countries. Despite the availability of treatments for this parasitic infection, treatment failures are alarmingly common. As a result, new therapeutic strategies are urgently needed to effectively combat this disease. On the other hand, within the eukaryotic nucleus, the nucleolus stands out as the most prominent structure. It plays a crucial role in coordinating ribosome biogenesis and is involved in vital processes such as maintaining genome stability, regulating cell cycle progression, controlling cell senescence, and responding to stress. Given its significance, the nucleolus presents itself as a valuable target for selectively inducing cell death in undesirable cells, making it a potential avenue for anti-Giardia treatments. Despite its potential importance, the Giardia nucleolus remains poorly studied and often overlooked. In light of this, the objective of this study is to provide a detailed molecular description of the structure and function of the Giardia nucleolus, with a primary focus on its involvement in ribosomal biogenesis. Likewise, it discusses the targeting of the Giardia nucleolus as a therapeutic strategy, its feasibility, and the challenges involved.
Sujet(s)
Nucléole , Giardia , Ribosomes , Nucléole/génétique , Nucléole/métabolisme , Giardia/cytologie , Giardia/génétique , ARN ribosomique/génétique , ADN ribosomique/génétique , ADN des protozoaires/génétique , ARN des protozoaires/génétique , Transcription génétique , Régulation de l'expression des gènes , Maturation post-transcriptionnelle des ARN/génétique , Ribosomes/génétique , Ribosomes/métabolisme , Giardiase/traitement médicamenteux , Antiparasitaires/usage thérapeutique , Développement de médicament/tendancesRÉSUMÉ
Antimicrobial resistance is a major obstacle for the treatment of infectious diseases and currently represents one of the most significant threats to global health. Staphylococcus aureus remains a formidable human pathogen with high mortality rates associated with severe systemic infections. S. aureus has become notorious as a multidrug resistant bacterium, which when combined with its extensive arsenal of virulence factors that exacerbate disease, culminates in an incredibly challenging pathogen to treat clinically. Compounding this major health issue is the lack of antibiotic discovery and development, with only two new classes of antibiotics approved for clinical use in the last 20 years. Combined efforts from the scientific community have reacted to the threat of dwindling treatment options to combat S. aureus disease in several innovative and exciting developments. This review describes current and future antimicrobial strategies aimed at treating staphylococcal colonization and/or disease, examining therapies that show significant promise at the preclinical development stage to approaches that are currently being investigated in clinical trials.
Sujet(s)
Antibactériens , Développement de médicament , Multirésistance bactérienne aux médicaments , Infections à staphylocoques , Staphylococcus aureus , Peptides antimicrobiens cationiques , Produits biologiques/usage thérapeutique , Antibactériens/usage thérapeutique , Adjuvants pharmaceutiques/usage thérapeutique , Synergie des médicaments , Immunoconjugués/usage thérapeutique , Phagothérapie , Développement de médicament/tendances , Infections à staphylocoques/traitement médicamenteux , Infections à staphylocoques/microbiologie , HumainsRÉSUMÉ
Approval of new agents to treat higher risk (HR) myelodysplastic syndrome (MDS) has stalled since the approval of DNA methyltransferase inhibitors (DNMTi). In addition, the options for patients with lower risk (LR) MDS who have high transfusion needs and do not harbor ring sideroblasts or 5q- syndrome are limited. Here, we review the current treatment landscape in MDS and identify areas of unmet need, such as treatment after failure of erythropoiesis-stimulating agents or DNMTis, TP53-mutated disease, and MDS with potentially targetable mutations. We discuss how our understanding of MDS pathogenesis can inform therapy development, including treating HR-MDS similarly to AML and pursuing therapies to address splicing factor mutations and dysregulated inflammation. We then bring a critical lens to current methodology of MDS studies and propose solutions to improve the efficiency and yield of these clinical trials, including using the most meaningful response metrics and expanding enrollment.